Adenosarcoma
M. Leonard Friedlander, Covens, A., Glasspool, R. M., Hilpert, F., Kristensen, G. B., Kwon, S., Selle, F., Small, W., Witteveen, E., and Russell, P.,
“Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract.”,
Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S78-82, 2014.
Adenosquamous/*drug therapy/pathology/*radiotherapy Carcinoma
C. W. Whitney, Sause, W., Bundy, B. N., Malfetano, J. H., Hannigan, E. V., Fowler, Jr., W. C., Clarke-Pearson, D. L., and Liao, S. Y.,
“Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study”,
J Clin Oncol, vol. 17, pp. 1339-48, 1999.
Adenosquamous/drug therapy/mortality/pathology/radiotherapy Carcinoma
P. J. Eifel, Winter, K., Morris, M., Levenback, C., Grigsby, P. W., Cooper, J., Rotman, M., Gershenson, D., and Mutch, D. G.,
“Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01”,
J Clin Oncol, vol. 22, pp. 872-80, 2004.
Adenosquamous/mortality/pathology/*therapy Carcinoma
T. Toita, Kitagawa, R., Hamano, T., Umayahara, K., Hirashima, Y., Aoki, Y., Oguchi, M., Mikami, M., Takizawa, K., and Group, C. Cancer Vul,
“Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG”,
Int J Gynecol Cancer, vol. 22, pp. 1420-6, 2012.
Adenosquamous/pathology/*surgery Cystadenocarcinoma
M. Signorelli, Lissoni, A., Cormio, G., Katsaros, D., Pellegrino, A., Selvaggi, L., Ghezzi, F., Scambia, G., Zola, P., Grassi, R., Milani, R., Giannice, R., Caspani, G., Mangioni, C., Floriani, I., Rulli, E., and Fossati, R.,
“Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study”,
Ann Surg Oncol, vol. 16, pp. 3431-41, 2009.
Adipokines Antigens
B. Gronlund, Hogdall, E. V., Christensen, I. J., Johansen, J. S., Norgaard-Pedersen, B., Engelholm, S. A., and Hogdall, C.,
“Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125)”,
Int J Biol Markers, vol. 21, pp. 141-8, 2006.
Adjuvant *Randomized Controlled Trials as Topic Societies
H. C. Kitchener, Hoskins, W. J., Small, W., Thomas, G. M., Trimble, E. L., and Group, C. Cancer Con,
“The development of priority cervical cancer trials: a Gynecologic Cancer InterGroup report”,
Int J Gynecol Cancer, vol. 20, pp. 1092-100, 2010.
Adjuvant Chromium Compounds/administration & dosage/adverse effects/*therapeutic use Cisplatin/administration & dosage Combined Modality Therapy Cyclophosphamide/administration & dosage Cystadenocarcinoma
R. C. Young, Brady, M. F., Nieberg, R. K., Long, H. J., Mayer, A. R., Lentz, S. S., Hurteau, J. A., and Alberts, D. S.,
“Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin–a gynecologic oncology group study”,
J Clin Oncol, vol. 21, pp. 4350-5, 2003.
Adjuvant Cisplatin/administration & dosage Confidence Intervals Disease-Free Survival Drug Administration Schedule Female Humans International Cooperation Middle Aged Neoplasm Staging Observation Odds Ratio Ovarian Neoplasms/*drug therapy/pathology/surge
N. Colombo, Guthrie, D., Chiari, S., Parmar, M. K. B., Qian, W., Swart, A. Marie, Torri, V., Williams, C., Lissoni, A., Bonazzi, C., and Collaborators, I. Collaborat,
“International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer”,
J Natl Cancer Inst, vol. 95, pp. 125-32, 2003.
Adjuvant Cisplatin/administration & dosage Confidence Intervals Disease-Free Survival Europe Female Humans International Cooperation Middle Aged Neoplasm Staging Observation Odds Ratio Ovarian Neoplasms/*drug therapy/*pathology/surgery Prognosis Risk Fac
J. B. Trimbos, Vergote, I. B., Bolis, G., Vermorken, J. B., Mangioni, C., Madronal, C., Franchi, M., Tateo, S., Zanetta, G., Scarfone, G., Giurgea, L., Timmers, P., Coens, C., Pecorelli, S., Collaborators, E. O. R. T. C. - A. C. T. I. O. N., Research, E. Organisati, and Neoplasm, Tof Cancer-,
“Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial”,
J Natl Cancer Inst, vol. 95, pp. 113-25, 2003.
Adjuvant Cisplatin/administration & dosage Disease-Free Survival Drug Administration Schedule Female Humans International Cooperation Middle Aged Neoplasm Staging Odds Ratio Ovarian Neoplasms/*drug therapy/pathology/surgery Risk Factors Survival Analysis
J. B. Trimbos, Parmar, M. K. B., Vergote, I. B., Guthrie, D., Bolis, G., Colombo, N., Vermorken, J. B., Torri, V., Mangioni, C., Pecorelli, S., Lissoni, A., Swart, A. Marie, Neoplasm, I. Collaborat, Research, E. Organisati, and Neoplasm, Tof Cancer,
“International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma”,
J Natl Cancer Inst, vol. 95, pp. 105-12, 2003.
Adjuvant Cisplatin/administration & dosage Etoposide/administration & dosage Female Follow-Up Studies Humans Middle Aged Neoplasm Staging Ovarian Neoplasms/*drug therapy/pathology/surgery Retrospective Studies Teratoma/*drug therapy/pathology/surgery Tre
G. Mangili, Scarfone, G., Gadducci, A., Sigismondi, C., Ferrandina, G., Scibilia, G., Vigano, R., Tateo, S., Villa, A., and Lorusso, D.,
“Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9)”,
Gynecol Oncol, vol. 119, pp. 48-52, 2010.
Adjuvant Cisplatin/administration & dosage/adverse effects Cyclophosphamide/administration & dosage/adverse effects Doxorubicin/administration & dosage/adverse effects Endometrial Neoplasms/*drug therapy/pathology/*radiotherapy/surgery Female Humans Midd
N. Susumu, Sagae, S., Udagawa, Y., Niwa, K., Kuramoto, H., Satoh, S., Kudo, R., and Group, J. Gynecologi,
“Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study”,
Gynecol Oncol, vol. 108, pp. 226-33, 2008.
Adjuvant Cisplatin/therapeutic use Cyclophosphamide/therapeutic use Female Follow-Up Studies Humans Middle Aged Multivariate Analysis Ovarian Neoplasms/drug therapy/mortality/*surgery Ovariectomy/*methods Prognosis Survival Analysis
M. E. L. van der Burg, van Lent, M., Buyse, M., Kobierska, A., Colombo, N., Favalli, G., Lacave, A. J., Nardi, M., Renard, J., and Pecorelli, S.,
“The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer”,
N Engl J Med, vol. 332, pp. 629-34, 1995.
Adjuvant Cisplatin/therapeutic use Female Gynecology/*standards Health Care Surveys Humans Hysterectomy *Physician's Practice Patterns Radiation Oncology/*standards Radiation-Sensitizing Agents/therapeutic use Radiotherapy Dosage Uterine Cervical Neoplas
D. K. Gaffney, du Bois, A., Narayan, K., Reed, N. Simon, Toita, T., Pignata, S., Blake, P., Portelance, L., Sadoyze, A., Potter, R., Colombo, A., Randall, M., Mirza, M. R., and Trimble, E. L.,
“Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG)”,
Int J Radiat Oncol Biol Phys, vol. 68, pp. 485-90, 2007.
Adjuvant Combined Modality Therapy Confidence Intervals Female Humans Middle Aged Neoplasm Recurrence
H. Mackay, Brady, M. F., Oza, A. M., Reuss, A., Pujade-Lauraine, E., Swart, A. Marie, Siddiqui, N. Ahmad, Colombo, N., Bookman, M. A., Pfisterer, J., du Bois, A., and InterGroup, G. Cancer,
“Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer”,
Int J Gynecol Cancer, vol. 20, pp. 945-52, 2010.
Adjuvant Combined Modality Therapy Female Humans Hysterectomy/methods International Cooperation Neoadjuvant Therapy Neoplasm Recurrence
H. C. Kitchener, Hoskins, W. J., Small, W., Thomas, G. M., Trimble, E. L., and Group, C. Cancer Con,
“The development of priority cervical cancer trials: a Gynecologic Cancer InterGroup report”,
Int J Gynecol Cancer, vol. 20, pp. 1092-100, 2010.
Adjuvant Databases
I. Ray-Coquard, Weber, B., Lotz, J. P., Tournigand, C., Provencal, J., Mayeur, D., Treilleux, I., Paraiso, D., Duvillard, P., Pujade-Lauraine, E., and Group, G. I. N. E. C. O.,
“Management of rare ovarian cancers: the experience of the French website "Observatory for rare malignant tumours of the ovaries" by the GINECO group: interim analysis of the first 100 patients”,
Gynecol Oncol, vol. 119, pp. 53-9, 2010.
Adjuvant Disease Progression Disease-Free Survival Female Humans Lymph Node Excision/methods Lymph Nodes/*surgery Middle Aged Neoplasms
D. ' T. Anna, Signorelli, M., Benedetti-Panici, P., Maggioni, A., Fossati, R., Fruscio, R., Milani, R., Bocciolone, L., Buda, A., Mangioni, C., Scambia, G., Angioli, R., Campagnutta, E., Grassi, R., and Landoni, F.,
“Systematic lymphadenectomy in ovarian cancer at second-look surgery: a randomised clinical trial”,
Br J Cancer, vol. 107, pp. 785-92, 2012.
Adjuvant Disease Progression Female Humans *Lymph Node Excision Lymph Nodes/pathology/surgery Lymphatic Metastasis Middle Aged Neoplasm Staging Ovarian Neoplasms/drug therapy/pathology/*surgery Pelvic Neoplasms/drug therapy/pathology/*surgery Risk Factor
A. Maggioni, P. Panici, B., Dell'Anna, T., Landoni, F., Lissoni, A., Pellegrino, A., Rossi, R. S., Chiari, S., Campagnutta, E., Greggi, S., Angioli, R., Manci, N., Calcagno, M., Scambia, G., Fossati, R., Floriani, I., Torri, V., Grassi, R., and Mangioni, C.,
“Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis”,
Br J Cancer, vol. 95, pp. 699-704, 2006.
Adjuvant Disease Progression Female Humans Lymph Node Excision/adverse effects/*methods Lymph Nodes/*pathology/surgery Lymphatic Metastasis Middle Aged Ovarian Neoplasms/drug therapy/mortality/pathology/*surgery Patient Selection Pelvis Predictive Value
P. B. Panici, Maggioni, A., Hacker, N., Landoni, F., Ackermann, S., Campagnutta, E., Tamussino, K., Winter, R., Pellegrino, A., Greggi, S., Angioli, R., Manci, N., Scambia, G., Dell'Anna, T., Fossati, R., Floriani, I., Rossi, R. S., Grassi, R., Favalli, G., Raspagliesi, F., Giannarelli, D., Martella, L., and Mangioni, C.,
“Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial”,
J Natl Cancer Inst, vol. 97, pp. 560-6, 2005.
Adjuvant Disease-Free Survival *Evaluation Studies as Topic Female Humans Middle Aged Ovarian Neoplasms/*blood/*diagnosis/drug therapy Prognosis Survival Rate *Treatment Outcome
B. Gronlund, Hogdall, C., Hilden, J., Engelholm, S. A., Hogdall, E. V., and Hansen, H. H.,
“Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?”,
J Clin Oncol, vol. 22, pp. 4051-8, 2004.
Adjuvant Drug Administration Schedule Female Humans Middle Aged Neoplasm Recurrence
J. G. Bell, Brady, M. F., Young, R. C., Lage, J., Walker, J. L., Look, K. Y., Rose, G. S., Spirtos, N. M., and Group, G. Oncology,
“Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study”,
Gynecol Oncol, vol. 102, pp. 432-9, 2006.
Adjuvant Endometrial Neoplasms/*drug therapy/pathology/*surgery Female Humans Japan Neoplasm Staging Paclitaxel/administration & dosage *Physician's Practice Patterns Postoperative Care/methods
Y. Watanabe, Kitagawa, R., Aoki, D., Takeuchi, S., Sagae, S., Sakuragi, N., Yaegashi, N., and Group, D. Committee,
“Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group”,
Gynecol Oncol, vol. 115, pp. 456-9, 2009.
Adjuvant Female Humans Hypercalcemia/*pathology Hysterectomy Middle Aged Neoplasm Staging Ovarian Neoplasms/blood/*classification/pathology/*therapy Ovariectomy Radiotherapy
M. L. Harrison, Hoskins, P., du Bois, A., Quinn, M., Rustin, G. J. S., Ledermann, J. A., Baron-Hay, S., and Friedlander, M. Leonard,
“Small cell of the ovary, hypercalcemic type – analysis of combined experience and recommendation for management. A GCIG study”,
Gynecol Oncol, vol. 100, pp. 233-8, 2006.
Pages
]